US Breast Cancer Diagnostics and Therapeutics Market Size, Trends, Demand, Analysis and Forecast 2019 to 2025

US breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.7% during the forecast period. The factors that enable the growth of the market include the prevalence of breast cancer and the initiative by the government and private organizations. Breast cancer is the most commonly diagnosed cancer type in the US. According to the American Cancer society, it is estimated that about 30% of newly diagnosed cancers in women are breast cancer in 2017. About 266,120 new cases of invasive breast cancer and about 63,960 cases of non-invasive breast cancer estimated in 2018 by the American Cancer Society. About 40,920 women died from breast cancer in 2018. The awareness program by the government and research funding also plays an important role in the growth of the breast cancer market in the US. The organization that is contributing to the breast cancer research funding and awareness program includes American Cancer Organization, National Cancer Institute (NCI), Susan G. Komen and others. American cancer provides 162 research grants for breast cancer and funded about $91 million for research in breast cancer.

Get Sample Copy of US Breast Cancer Diagnostics and Therapeutics Market at: https://www.omrglobal.com/request-sample/us-breast-cancer-diagnostics-therapeutics-market

The companies which are contributing to the growth of the US breast cancer diagnostics and therapeutics market include, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Hologic Inc., Halozyme, Inc., Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc. And others.

US breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others.

For More Information, get A full report of US Breast Cancer Diagnostics and Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/us-breast-cancer-diagnostics-therapeutics-market

The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Market Segmentation

Breast Cancer Diagnostics and Therapeutics Market by Cancer Type

o Ductal Carcinoma In-Situ (DCIS)
o Invasive Ductal Carcinoma (IDC)
o Triple Negative Breast Cancer (TNBC)
o Inflammatory Breast Cancer
o Others (Invasive lobular carcinoma)

Breast Cancer Diagnostics and Therapeutics Market by Diagnostics

o Mammography
o Biopsy
o PET/CET
o Ultrasound
o Others (MRI)

Breast Cancer Diagnostics and Therapeutics Market by Therapeutics

o Chemotherapy
o Hormone Therapy
o Targeted Therapy
o Others (Radiation Therapy, Surgery)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/us-breast-cancer-diagnostics-therapeutics-market

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

This release was published on openPR.